Log in or register to see all Alerts
New HTA Decisions in Scotland
June 2020
Drug name
IMBRUVICA® (ibrutinib)
Company
Janssen-Cilag Ltd
Decision date
11/11/2019
Therapeutic area
Cancer
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia who have recieved at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, ibrutinib (IMBRUVICA®) is not recommended for use within NHS Scotland.
Summary
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result the SMC cannot recommend its use within NHS Scotland.